Amneal Pharmaceuticals, Inc. reaffirmed earnings guidance for the full year 2021. For the year, the company expects net revenue to be approximately $2.1 billion.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.89 USD | -1.57% |
|
+2.07% | +13.51% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.51% | 2.13B | |
+41.96% | 630B | |
-7.15% | 350B | |
+18.77% | 328B | |
+8.79% | 298B | |
+18.02% | 246B | |
+1.27% | 225B | |
+11.95% | 218B | |
+3.68% | 160B | |
-4.38% | 156B |
- Stock Market
- Equities
- AMRX Stock
- News Amneal Pharmaceuticals, Inc.
- Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full Year 2021